Coordination of interleukin-6 biology by membrane bound and soluble receptors.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-4615-0685-0_19PMID 11774558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

  2001cited by this paper
• Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells.

  2001cited by this paper
• Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins.

  2001cited by this paper
• Astrocytic Alterations in Interleukin-6/Soluble Interleukin-6 Receptor α Double-Transgenic Mice

  2000cited by this paper
• Astrocytic alterations in interleukin-6/Soluble interleukin-6 receptor alpha double-transgenic mice.

  2000cited by this paper
• New perspectives on the design of cytokines and growth factors.

  2000cited by this paper
• Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins.

  2000cited by this paper
• Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo

  2000cited by this paper
• The importance of shedding of membrane proteins for cytokine biology.

  2000cited by this paper
• New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?

  1999cited by this paper
• The role of COX-2 in intestinal cancer.

  1999cited by this paper
• Neural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors

  1999cited by this paper
• Receptor Recognition Sites of Cytokines Are Organized as Exchangeable Modules

  1999cited by this paper
• Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor.

  1999cited by this paper
• Sympathetic neurons can produce and respond to interleukin 6.

  1998cited by this paper
• A New Type of Cytokine Receptor Antagonist Directly Targeting gp130*

  1998cited by this paper
• Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis.

  1998cited by this paper
• Gp130 and the interleukin-6 family of cytokines.

  1997cited by this paper
• A bioactive designer cytokine for human hematopoietic progenitor cell expansion

  1997cited by this paper
• Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

  1997cited by this paper
• Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6–sIL-6R Double Transgenic Mice

  1997cited by this paper
• The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6

  1996cited by this paper
• Soluble receptors for cytokines and growth factors: generation and biological function.

  1994cited by this paper
• Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

  1993cited by this paper
• Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins.

  1992cited by this paper
• Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

  1989cited by this paper

• Meprin β activity modulates cellular proliferation via trans-signaling IL-6-mediated AKT/ERK pathway in IR-induced kidney injury

  2025cites this paper
• Meprin β activity modulates cellular proliferation via trans-signaling IL-6-mediated AKT/ERK pathway in IR-induced kidney injury

  2025cites this paper
• The SoS conductor: Orchestrating resources with iterative agent‐based reinforcement learning

  2024cites this paper
• Interleukin-6 trans-signaling regulates monocyte chemoattractant protein-1 production in immune-mediated necrotizing myopathy.

  2024cites this paper
• Transcriptional and Cellular Response of hiPSC-derived Microglia-Neural Progenitor Co-Cultures Exposed to IL-6

  2024cites this paper
• Interleukin-6-Positive Immune Cells as a Possible New Immunologic Marker Associated With the Colorectal Cancer Prognosis

  2024cites this paper
• The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure

  2022cites this paper
• COVID-19 infection: an overview on cytokine storm and related interventions

  2022cites this paper
• Natural products as antiinflammatory agents

  2020cites this paper
• Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer.

  2020cites this paper
• IL-6 Activities in the Tumour Microenvironment. Part 1

  2019cites this paper
• Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

  2019cites this paper
• Dual ARB/NEP inhibition improved endothelial function in metabolic syndrome

  2019cites this paper
• EVALUATION OF INTERLEUKIN-6 (IL-6) AS A TUMOR MARKER FOR URINARY BLADDER CANCER

  2015cites this paper
• STAT 3 Signaling in Cancer

  2015cites this paper
• EVALUATION OF INTERLEUKIN-6 (IL-6) AS A TUMOR MARKER FOR URINARY BLADDER CANCER

  2015cites this paper
• The varying faces of IL-6: From cardiac protection to cardiac failure.

  2015cites this paper
• STAT3 Signaling in Cancer

  2015cites this paper
• Personalisation of therapy in advanced colorectal cancer

  2015cites this paper
• VirusesImmune Response to DNA and RNA Soluble Interleukin-6 Receptor-Mediated

  2014cites this paper
• Redox-Mediated and Ionizing-Radiation-Induced Inflammatory Mediators in Prostate Cancer Development and Treatment

  2014cites this paper
• Do baseline Cereblon gene expression and IL‐6 receptor expression determine the response to thalidomide–dexamethasone treatment in Multiple myeloma patients?

  2014cites this paper
• The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).

  2014cites this paper
• Interleukin-6 and Exercise-Induced Cardioprotection

  2014cites this paper
• Obesity, Inflammation, and Prostate Cancer

  2013cites this paper
• Soluble Interleukin-6 Receptor-Mediated Innate Immune Response to DNA and RNA Viruses

  2013cites this paper
• Role of Adipose Cells in Tumor Microenvironment

  2013cites this paper
• REDOX-REGULATED RELB-AR AXIS MEDIATES PROSTATE SPECIFIC ANTIGEN EXPRESSION: INSIGHT IN PROSTATE CANCER RESPONSE TO RADIATION THERAPY

  2013cites this paper
• Influence of local inflammation of the peritoneal membrane on diuresis and residual renal function in patients treated with peritoneal dialysis

  2012cites this paper
• Protection against Angiotensin II-induced endothelial dysfunction and hypertension via small molecule inhibitors of signal transducer and activator of transcription 3

  2012cites this paper
• Biology of castration-recurrent prostate cancer.

  2012cites this paper
• The role of extra and intra vascular cells and theirmolecules in modulating glomerular inflammationduring health and disease

  2012cites this paper
• Elevated IL-6 Receptor Expression on CD4+ T Cells contributes to the increased Th17 Responses in patients with Chronic Hepatitis B

  2011cites this paper
• Exploring the pathogenic potential of myelin-reactive Th1 and Th17 cells in central nervous system autoimmune disease

  2011cites this paper
• IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.

  2011cites this paper
• IL-6/IL-6R as a potential key signaling pathway in prostate cancer development GUIDELINES CLINICAL PRACTICE World Journal of Clinical Oncology

  2011cites this paper
• Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.

  2010cites this paper
• Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.

  2010cites this paper
• The response of circulating levels of the interleukin-6/interleukin-6 receptor complex to exercise in young men.

  2009cites this paper
• Role of STAT3 and GATA-1 interactions in gamma-globin gene expression.

  2009cites this paper
• The effect of interleukin‐6 and the interleukin‐6 receptor on glucose transport in mouse skeletal muscle

  2009cites this paper
• Experimental Physiology - Research Paper The effect of interleukin-6 and the interleukin-6 receptor on glucose transport in mouse skeletal muscle

  2009cites this paper
• Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.

  2009cites this paper
• Expression profiling and Ingenuity biological function analyses of interleukin-6- versus nerve growth factor-stimulated PC12 cells

  2009cites this paper
• IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier.

  2008cites this paper
• Pravastatin Prevents Aortic Atherosclerosis via Modulation of Signal Transduction and Activation of Transcription 3 (STAT3) to Attenuate Interleukin-6 (IL-6) Action in ApoE Knockout Mice

  2008cites this paper
• IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human myoblasts.

  2008cites this paper
• Bone marrow stromal cells reduce ischemia-induced astrocytic activation in vitro.

  2008cites this paper
• Cytokines: from gut inflammation to colorectal cancer.

  2008cites this paper
• Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.

  2007cites this paper
• Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.

  2007cites this paper
• Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance.

  2007cites this paper
• STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo.

  2007cites this paper
• Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer

  2006cites this paper
• Importance of soluble cytokine receptors for inflammation associated cancer

  2006cites this paper
• Der Signaltransduktor gp130: NMR-spektroskopische Untersuchungen zur Strukturaufklärung der membranproximalen Domänen

  2006cites this paper
• Interleukin-6 trans-signaling in inflammatory bowel disease.

  2006cites this paper
• Designer cytokines for human haematopoietic progenitor cell expansion: impact for tissue regeneration.

  2006cites this paper
• Endometrial receptivity markers, the journey to successful embryo implantation.

  2006cites this paper
• Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling.

  2006cites this paper
• Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer

  2006cites this paper
• IL-6 transsignaling: the in vivo consequences.

  2005cites this paper
• The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury.

  2005cites this paper
• Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane

  2005cites this paper
• Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice.

  2004cites this paper
• Interleukin-6 biology is coordinated by membrane bound and soluble receptors.

  2003cites this paper
• Arteriosclerosis, Thrombosis, and Vascular Biology

  year unknowncites this paper